Merkel cell carcinoma of the thigh: case report and review of the literature
Open Access
- 1 January 2019
- journal article
- review article
- Published by Taylor & Francis Ltd in OncoTargets and Therapy
- Vol. ume 12, 535-540
- https://doi.org/10.2147/ott.s182169
Abstract
Merkel cell carcinoma of the thigh: case report and review of the literature Wen Jiang,* Jiali Xu,* Rong Wang, Tingting Wang, Yongqian Shu, Lianke Liu Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China *These authors contributed equally to this work Background: Merkel cell carcinoma (MCC) is a kind of cutaneous neuroendocrine cancer with a poor prognosis. It is characterized by a high rate of recurrence and metastases, including distant metastases and regional nodal metastases. Clinically, MCC often manifests as obvious single painless hard nodules visible in sun irradiation of diameter 2 cm, with rapid growth and metastases, especially lymph node metastases. Due to the aspecific nature of MCC, it is often confused with other skin cancers. Exploring different treatments of MCC is necessary.Case presentation: The current study describes the case of an 86-year-old retired man, who presented with a 2.5×2.0×1.2 cm red nodule on the right thigh, which was initially diagnosed as subcutaneous small cell cancer. Upon histological and immunohistochemical analysis, the tumor was consistent with a diagnosis of MCC.Results: Antiangiogenic therapy combining endostar and apatinib was administered and a partial response achieved after 2.0 months of treatment, and 6.5 months of progression-free survival was achieved. Overall survival was 13.0 months.Conclusion: We believe that antiangiogenic therapy is an extremely effective treatment for MCC, especially for patients who cannot tolerate chemotherapy and radiotherapy. Keywords: Merkel cell carcinoma, antiangiogenic therapy, endostar, apatinibKeywords
This publication has 37 references indexed in Scilit:
- Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II TrialJournal of Clinical Oncology, 2013
- Tumor Location Is an Independent Prognostic Factor in Head and Neck Merkel Cell CarcinomaOtolaryngology -- Head and Neck Surgery, 2011
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivoCancer Science, 2011
- Tyrosine Kinase Receptor Flt/VEGFR Family: Its Characterization Related to Angiogenesis and CancerGenes & Cancer, 2010
- Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignanciesBMC Cancer, 2010
- Merkel cell carcinomaCancer, 2008
- Clonal Integration of a Polyomavirus in Human Merkel Cell CarcinomaScience, 2008
- Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cellsBiochemical and Biophysical Research Communications, 2007
- Merkel cell carcinoma adjuvant therapy: Current data support radiation but not chemotherapyJournal of the American Academy of Dermatology, 2007
- Merkel Cell Carcinoma: Improved Outcome With the Addition of Adjuvant TherapyJournal of Clinical Oncology, 2005